286 related articles for article (PubMed ID: 16990798)
1. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase.
Allen MD; Grummitt CG; Hilcenko C; Min SY; Tonkin LM; Johnson CM; Freund SM; Bycroft M; Warren AJ
EMBO J; 2006 Oct; 25(19):4503-12. PubMed ID: 16990798
[TBL] [Abstract][Full Text] [Related]
2. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.
Bach C; Mueller D; Buhl S; Garcia-Cuellar MP; Slany RK
Oncogene; 2009 Feb; 28(6):815-23. PubMed ID: 19060922
[TBL] [Abstract][Full Text] [Related]
4. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.
Cierpicki T; Risner LE; Grembecka J; Lukasik SM; Popovic R; Omonkowska M; Shultis DD; Zeleznik-Le NJ; Bushweller JH
Nat Struct Mol Biol; 2010 Jan; 17(1):62-8. PubMed ID: 20010842
[TBL] [Abstract][Full Text] [Related]
5. C1188D mutation abolishes specific recognition between MLL1-CXXC domain and CpG site by inducing conformational switch of flexible N-terminal.
Chen J; Qi Y; Duan Y; Duan M; Yang M
Proteins; 2020 Nov; 88(11):1401-1412. PubMed ID: 32519403
[TBL] [Abstract][Full Text] [Related]
6. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
Ayton PM; Chen EH; Cleary ML
Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
[TBL] [Abstract][Full Text] [Related]
7. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.
Chang PY; Hom RA; Musselman CA; Zhu L; Kuo A; Gozani O; Kutateladze TG; Cleary ML
J Mol Biol; 2010 Jul; 400(2):137-44. PubMed ID: 20452361
[TBL] [Abstract][Full Text] [Related]
8. ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection.
Long HK; Blackledge NP; Klose RJ
Biochem Soc Trans; 2013 Jun; 41(3):727-40. PubMed ID: 23697932
[TBL] [Abstract][Full Text] [Related]
9. MLL translocations, histone modifications and leukaemia stem-cell development.
Krivtsov AV; Armstrong SA
Nat Rev Cancer; 2007 Nov; 7(11):823-33. PubMed ID: 17957188
[TBL] [Abstract][Full Text] [Related]
10. The structural basis for selective binding of non-methylated CpG islands by the CFP1 CXXC domain.
Xu C; Bian C; Lam R; Dong A; Min J
Nat Commun; 2011; 2():227. PubMed ID: 21407193
[TBL] [Abstract][Full Text] [Related]
11. DNA Sequence Recognition of Human CXXC Domains and Their Structural Determinants.
Xu C; Liu K; Lei M; Yang A; Li Y; Hughes TR; Min J
Structure; 2018 Jan; 26(1):85-95.e3. PubMed ID: 29276034
[TBL] [Abstract][Full Text] [Related]
12. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).
Ono R; Taki T; Taketani T; Taniwaki M; Kobayashi H; Hayashi Y
Cancer Res; 2002 Jul; 62(14):4075-80. PubMed ID: 12124344
[TBL] [Abstract][Full Text] [Related]
13. Different binding properties and function of CXXC zinc finger domains in Dnmt1 and Tet1.
Frauer C; Rottach A; Meilinger D; Bultmann S; Fellinger K; Hasenöder S; Wang M; Qin W; Söding J; Spada F; Leonhardt H
PLoS One; 2011 Feb; 6(2):e16627. PubMed ID: 21311766
[TBL] [Abstract][Full Text] [Related]
14. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.
Birke M; Schreiner S; García-Cuéllar MP; Mahr K; Titgemeyer F; Slany RK
Nucleic Acids Res; 2002 Feb; 30(4):958-65. PubMed ID: 11842107
[TBL] [Abstract][Full Text] [Related]
15. Specificity of MLL1 and TET3 CXXC domains towards naturally occurring cytosine modifications.
Stroynowska-Czerwinska A; Piasecka A; Bochtler M
Biochim Biophys Acta Gene Regul Mech; 2018 Dec; 1861(12):1093-1101. PubMed ID: 30352306
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of MLL PHD3 and RNA recognition by the Cyp33 RRM domain.
Hom RA; Chang PY; Roy S; Musselman CA; Glass KC; Selezneva AI; Gozani O; Ismagilov RF; Cleary ML; Kutateladze TG
J Mol Biol; 2010 Jul; 400(2):145-54. PubMed ID: 20460131
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for activity regulation of MLL family methyltransferases.
Li Y; Han J; Zhang Y; Cao F; Liu Z; Li S; Wu J; Hu C; Wang Y; Shuai J; Chen J; Cao L; Li D; Shi P; Tian C; Zhang J; Dou Y; Li G; Chen Y; Lei M
Nature; 2016 Feb; 530(7591):447-52. PubMed ID: 26886794
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
[TBL] [Abstract][Full Text] [Related]
20. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.
Li BE; Ernst P
Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
